Previous 10 | Next 10 |
Presented preliminary Phase 1a/1b trial findings at ESMO 2021 for NGM120, a GFRAL antagonist antibody product candidate, that showed the drug was well tolerated in advanced solid tumors and provided encouraging initial signals of anti-cancer activity in patients with metastatic pancreatic...
Investing in biopharma companies is a high-risk/high-reward approach that makes millionaires out of average investors, but it can also turn a promising investment into a truly undesirable portfolio holding. If revenue is not yet being generated from products, a company's stock price can rel...
The following slide deck was published by NGM Biopharmaceuticals, Inc. in conjunction with this event. For further details see: NGM Biopharmaceuticals (NGM) Investor Presentation
Gainers: PRAA +12.4%. ASPU +7.7%. GRTS +4.0%. ANPC +3.8%. OTMO +3.6%. Losers: OPK -3.2%. CSGS -2.0%. CDZI -1.9%. GRPN -1.5%. NGM -1.5%. For further details see: PRAA, ASPU, OPK and CSGS among after hours movers
NGM120 is a novel antagonist antibody that binds GFRAL and inhibits GDF15 signaling for the potential treatment of cancer NGM120 has been well tolerated to date in patients in the Phase 1a/1b study with no dose-limiting toxicities All six evaluable metastatic pancreatic cancer p...
M&A headlines and analyst comments sparked some high-profile movement in Monday's midday market action. This included reports that Qualcomm (NASDAQ:QCOM) has submitted a binding $4.6B offer for Veoneer (NYSE:VNE). Meanwhile, Honest Company (NASDAQ:HNST) and NGM Biopharmaceuticals (NASDAQ:...
Gainers: IVERIC bio (NASDAQ:ISEE) +56%, Endo (NASDAQ:ENDP) +46%, NGM Biopharmaceuticals (NASDAQ:NGM) +16%, Arbutus Biopharma (NASDAQ:ABUS) +15%, CareMax (NASDAQ:CMAX) +11%. Losers: Apellis Pharmaceuticals (NASDAQ:APLS) -50%, Mersana Therapeuti...
Publication describes NGM’s discovery of ILT3’s functional ligand, fibronectin, a key component of the tumor stroma ILT3-fibronectin interactions within the tumor microenvironment may form a stromal checkpoint that actively suppresses myeloid cell function and inhibits a...
Completed enrollment in 320-patient Phase 2 CATALINA study of NGM621, an anti-complement C3 antibody, for the treatment of geographic atrophy; topline data expected in second half of 2022 Initiated a Phase 1/2 clinical trial of NGM707, an ILT2/ILT4 dual antagonist antibody, in patie...
Geographic atrophy is a progressive, irreversible retinal degenerative disease that can lead to blindness, with no currently approved treatments NGM621 is a monoclonal antibody against complement C3, a protein implicated in the pathophysiology of geographic atrophy, and is engineered ...
News, Short Squeeze, Breakout and More Instantly...
NGM Biopharmaceuticals Inc. Company Name:
NGM Stock Symbol:
NYSE Market:
NGM Biopharmaceuticals Inc. Website:
SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (“NGM Bio”) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that Atlas Neon Parent, Inc. (“Parent”), an...
SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongo...
--Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab) with expected completion of enrollment in the second quarter of 202...